Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
“Michael Rossi shares Y-mAbs’ belief that our future is bright as we continue to commercialize DANYELZA (naxitamab-gqgk) and build world-class capabilities working to develop and commercialize new innovative treatments that improve the lives of patients with cancer.
- “Michael Rossi shares Y-mAbs’ belief that our future is bright as we continue to commercialize DANYELZA (naxitamab-gqgk) and build world-class capabilities working to develop and commercialize new innovative treatments that improve the lives of patients with cancer.
- “We are extremely grateful for Thomas’s successful leadership and dedication as Interim CEO.
- We look forward to Thomas’s continued leadership in his new role as Vice Chairman of the Board of Directors and Chief Business Officer of Y-mAbs.”
Mr. Rossi said, “I have long admired Y-mAbs as a leader in the development of transformative cancer therapies. - Y-mAbs is a pioneer in pretargeted radioimmunotherapy with its SADA Technology and diverse pipeline of promising SADA programs, and a science-driven, patient-first culture.